ABSTRACT:Objective To explore the expression of Survivin (SVV) protein in colorectal carcinogenesis and its clinical significance. Methods Immunohistochemistry staining was performed by two-step EnVisionTM technique for the paraffin sections, which included 90 adenomas, 25 ademomas with high-grade glandular intraepithelial neoplasia, and 108 colorectal adenocarcinomas. Results Expressions of SVV, P53, and Bcl-2 were observed in tumor cells of the sections. The positive rate of SVV in tubular adenomas, villous adenomas, and tubulovillous adenomas were 30% (12/40), 40.9% (9/22), and 35.8% (10/28), respectively. The positive rate of SVV in tubulovillous adenomas with high-grade glandular intraepithelial neoplasia were 68% (17/25). The positive rate of SVV in carcinomas of stage A, B, and C were 75% (27/36), 81.3% (26/32), and 95% (38/40), respectively. SVV expressions among the three types of adenomas without neoplasia were not significantly different（P>0.05）. SVV expression between each type of the above-mentioned ademoma and tubulovillous adenoma with high-grade glandular intraepithelial neoplasia or different Dukes stages of colorectal carcinoma was significantly different (P<0.05). SVV expressions in adenocarcinomas and adenomas with high grade glandular intraepithelial neoplasia were significantly higher than those in adenomas ( P<0.01). The expressions of P53 and Bcl-2 had no significant difference among them. No association was noted between SVV expression and P53 or Bcl-2 expression （P=0.487, P=0.437). Conclusions SVV is abnormally expressed in the early stage of colorectal carcinogenesis,which may be correlated with the carcinogenesis of colorectal ademoma. SVV expression may be useful to distinguish adenocarcinoma from adenoma in colorectal carcinogenesis.
Key words
survivin /
adenoma /
carcinoma /
colarectal
{{custom_keyword}} /
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
[1]Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin expressed in cancer and lymphoma[J]. Nature Med, 1997, 3(8):917-921.
[2]Adida C, Crotty PL, McGrath J, et al. Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation[J]. Am J Pathol, 1998, 152(1):43-49.
[3]Adida C, Berrebi D, Peuchmaur M, et al. Anti-apoptosis gene, survivin, and prognosis of neuroblastoma[J]. Lancet, 1998, 351(9106):882-883.
[4]杨 景,柳凤轩,阎晓初,等. Survivin 在结直肠癌组织中的表达的临床意义及其与细胞凋亡、血管生成的关系［J］. 癌症,2005, 24(1):116-120.
[5]Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays[J]. J Immunol Methods, 1983, 65(1-2):55-63.
[6]Monzo M, Rosell R, Felip E, et al. A novel anti-apoptosis gene:re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers[J]. J Clin Oncol, 1999, 17(7):2100-2104.
[7]Tanaka K, Iwamoto S, Gon G, et al. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas[J]. Clin Cancer Res, 2000, 6(1):127-134.
[8]关 健,陈 杰. Survivin—一个新的肿瘤特异性的抑制凋亡因子[J].中国医学科学院学报,2001, 23(5):532-534.
[9]姚红兵, 吴爱国,黄宗海. Survivin 在结直肠腺癌中的表达及其临床意义[J]. 第一军医大学学报,2004,24（12）：1412-1415.
[10]Altieri DC, Marchisio C. Survivin apoptosis: an interloper between cell death and cell proliferation in cancer[J]. Lab Invest,1999, 79(11):1327-1333.
[11]Ponnelle T, Chapusot C, Martin L, et al. Cellular localization of survivin: impact on the prognosis in colorectal cancer[J]. J Cancer Res Clin Oncol, 2005, 131(8):504-510.
[12]Tonini G, Vincenzi B, Santini D, et al. Nuclear and cytoplasmic expression of survivin in 67 surgically resected pancreatic cancer patients[J]. Br J Cancer, 2005, 92(12):2225-2232.
[13]Li F, Yang J, Ramnath N, et al. Nuclear or cytoplasmic expression of survivin: what is the significance[J]? Int J Cancer, 2005, 114(4):509-512.
{{custom_fnGroup.title_en}}
Footnotes
{{custom_fn.content}}
PDF(119 KB)
京ICP备06002729号-1 京公网安备110402430088
